Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Senior Vice President | December 01, 2012 | December 04, 2012 |
| AbbVie Inc.ABBV · Entity 2800 | Vice Chairman | November 16, 2020 | November 18, 2020 |
| Solventum CorpSOLV · Entity 1645 | Director | May 15, 2026 | May 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date December 01, 2012 · Filed December 04, 2012
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 95,696 |
Ending reported balance
After 2012-12-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2012-11-16 · Gift · Disposed 40,442 · Balance 77,243 Row 2 · 2012-12-01 · Grant · Acquired 18,453 · Balance 95,696 F1: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards will cliff vest after January 1, 2016, subject to AbbVie reaching a minimum average return on equity target for the period 2013 through 2015. The awards include the right to have stock withheld for tax purposes. |
| Common shares without par valueSEC Table I · non-derivative | IndirectMaria Cristina Alban 2007 Declaration of Trust | 40,442 |
Reported balance
After 2012-11-16 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2012-11-16 · Gift · Acquired 40,442 · Balance 40,442 F2: Held in the Maria Cristina Alban 2007 Declaration of Trust. The reporting person's spouse is trustee of the trust. The trust is revocable by his spouse. The reporting person disclaims beneficial ownership of these securities. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards will cliff vest after January 1, 2016, subject to AbbVie reaching a minimum average return on equity target for the period 2013 through 2015. The awards include the right to have stock withheld for tax purposes.
F2: Held in the Maria Cristina Alban 2007 Declaration of Trust. The reporting person's spouse is trustee of the trust. The trust is revocable by his spouse. The reporting person disclaims beneficial ownership of these securities.
AbbVie Inc.
Report date November 16, 2020 · Filed November 18, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 114,899 |
Ending reported balance
After 2020-11-16 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-11-16 · Exercise / conversion · Acquired 115,830 · Balance 230,729 Row 2 · 2020-11-16 · Sale · Disposed 115,830 · Balance 114,899 |
| Option(Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.88 · Expires 2023-02-13 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-11-16 · Exercise / conversion · Disposed 115,830 · Balance 0 F2: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. |
| Common Stock, $0.01 par valueSEC Table I · non-derivative | IndirectMaria Cristina Alban 2007 Declaration of Trust | 40,442 |
Reported balance
Holding disclosure · report date 2020-11-16 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 40,442 F1: Held in the Maria Cristina Alban 2007 Declaration of Trust. The reporting person's spouse is trustee of the trust. |
Filing footnotes · ownership attribution and instrument terms
F1: Held in the Maria Cristina Alban 2007 Declaration of Trust. The reporting person's spouse is trustee of the trust.
F2: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.
Solventum Corp
Report date May 15, 2026 · Filed May 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 3,300 |
Reported balance
After 2026-05-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-15 · Grant · Acquired 3,300 · Balance 3,300 F1: Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement. F2: The RSUs shall fully vest on May 15, 2027, subject to continued service through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.
F2: The RSUs shall fully vest on May 15, 2027, subject to continued service through the vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SpringWorks Therapeutics, Inc.
Report date July 01, 2025 · Filed July 02, 2025
Section 16 reporting ended · disclosed 2025-07-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-07-01 transaction · row 1
1 source rowRow 1 · 2025-07-01 · Disposition to issuer · Disposed 28,861 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F2: Includes 13,480 shares underlying restricted stock units (each, an "RSU") granted under the Issuer's 2019 Stock Option and Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of Issuer common stock. F3: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and automatically converted into the right to receive $47.00 in cash, without interest and subject to any required tax withholding (the "Merger Consideration"). F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding RSU, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the Merger Consideration payable with respect to such RSU multiplied by (ii) the total number of shares of Issuer common stock subject to such RSU immediately prior to the Effective Time (each a "Parent Cash-Based RSU Award"). Each Parent Cash-Based RSU Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such RSU immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based RSU Award will vest, subject to the applicable holder's continued employment with Parent through such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.93 | Direct | 0 |
Reported balance
After 2025-07-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-07-01 · Disposition to issuer · Disposed 30,160 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 6) F6: (Continued from footnote 5) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.27 | Direct | 0 |
Reported balance
After 2025-07-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-07-01 · Disposition to issuer · Disposed 13,774 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 6) F6: (Continued from footnote 5) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.77 | Direct | 0 |
Reported balance
After 2025-07-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-07-01 · Disposition to issuer · Disposed 12,216 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 6) F6: (Continued from footnote 5) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger").
F2: Includes 13,480 shares underlying restricted stock units (each, an "RSU") granted under the Issuer's 2019 Stock Option and Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of Issuer common stock.
F3: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and automatically converted into the right to receive $47.00 in cash, without interest and subject to any required tax withholding (the "Merger Consideration").
F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding RSU, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the Merger Consideration payable with respect to such RSU multiplied by (ii) the total number of shares of Issuer common stock subject to such RSU immediately prior to the Effective Time (each a "Parent Cash-Based RSU Award"). Each Parent Cash-Based RSU Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such RSU immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based RSU Award will vest, subject to the applicable holder's continued employment with Parent through such date.
F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 6)
F6: (Continued from footnote 5) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 14, 2017 Filed Jun 15, 2017 21:05 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 45,800 | $70.00 | $3,206,000.00 |
DisclosureSEC source: 0001179110-17-009114 · edgar.xml · nonDerivative · entry 2 ALBAN CARLOS · CIK 0001474632 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,745 Read SEC document |
| June 14, 2017 Filed Jun 15, 2017 21:05 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon stock, $0.01 par value | 45,800 | $24.21 | $1,108,735.56 |
DisclosureSEC source: 0001179110-17-009114 · edgar.xml · nonDerivative · entry 1 ALBAN CARLOS · CIK 0001474632 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,545 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2017 Filed May 8, 2017 21:13 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 43,000 | $67.00 | $2,881,000.00 |
DisclosureSEC source: 0001179110-17-006837 · edgar.xml · nonDerivative · entry 1 ALBAN CARLOS · CIK 0001474632 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,745 Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 23:10 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 34,721 | $62.22 | $2,160,340.62 |
DisclosureSEC source: 0001179110-17-003699 · edgar.xml · nonDerivative · entry 1 ALBAN CARLOS · CIK 0001474632 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,745 Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 22:50 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 95,750 | $0.00 Strike: $61.36 | $0.00 |
DisclosureSEC source: 0001179110-17-002804 · edgar.xml · derivative · entry 4 ALBAN CARLOS · CIK 0001474632 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,750 Underlying: Common stock · 95,750 shares Expires 2027-02-15 F4 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exercisable in annual increments of 31,917 on 02/16/2018, 31,916 on 02/16/2019, and 31,917 on 02/16/2020. Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 22:50 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 13,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002804 · edgar.xml · nonDerivative · entry 2 ALBAN CARLOS · CIK 0001474632 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,466 F2 · shares: Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2017. Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 22:50 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 29,672 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002804 · edgar.xml · nonDerivative · entry 1 ALBAN CARLOS · CIK 0001474632 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,116 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on adjusted earnings per share and relative total shareholder return measures. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2017. Read SEC document |
| May 10, 2016 Filed May 12, 2016 21:39 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 47,438 | $63.52 | $3,013,261.76 |
DisclosureSEC source: 0001179110-16-024454 · edgar.xml · nonDerivative · entry 1 ALBAN CARLOS · CIK 0001474632 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,444 Read SEC document |
| February 29, 2016 Filed Mar 2, 2016 22:18 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 39,930 | $56.00 | $2,236,080.00 |
DisclosureSEC source: 0001179110-16-020675 · edgar.xml · nonDerivative · entry 1 ALBAN CARLOS · CIK 0001474632 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,882 Read SEC document |
| February 18, 2016 Filed Feb 22, 2016 22:05 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 79,870 | $0.00 Strike: $54.86 | $0.00 |
DisclosureSEC source: 0001179110-16-019777 · edgar.xml · derivative · entry 1 ALBAN CARLOS · CIK 0001474632 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,870 Underlying: Common stock · 79,870 shares Expires 2026-02-17 F1 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exerciseable in annual increments of 26,624 on 02/18/2017, 26,623 on 02/18/2018, and 26,623 on 02/18/2019. Read SEC document |
| February 28, 2015 Filed Mar 3, 2015 23:03 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 7,200 | $60.50 | $435,600.00 |
DisclosureSEC source: 0001179110-15-004093 · edgar.xml · nonDerivative · entry 2 ALBAN CARLOS · CIK 0001474632 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,812 Read SEC document |
| February 27, 2015 Filed Mar 3, 2015 23:03 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 12,706 | $60.52 | $768,967.12 |
DisclosureSEC source: 0001179110-15-004093 · edgar.xml · nonDerivative · entry 1 ALBAN CARLOS · CIK 0001474632 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,012 Read SEC document |
| February 19, 2015 Filed Feb 23, 2015 22:07 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 101,960 | $0.00 Strike: $58.88 | $0.00 |
DisclosureSEC source: 0001179110-15-003160 · edgar.xml · derivative · entry 3 ALBAN CARLOS · CIK 0001474632 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,960 Underlying: Common stock · 101,960 shares Expires 2025-02-18 F3 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exerciseable in annual increments of 33,987 on 02/19/2016, 33,986 on 02/19/2017, and 33,987 on 02/19/2018. Read SEC document |
| February 19, 2015 Filed Feb 23, 2015 22:07 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 51,580 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-15-003160 · edgar.xml · nonDerivative · entry 1 ALBAN CARLOS · CIK 0001474632 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,718 F1 · shares: These securities represent performance vested restricted stock awards under the AbbVie 2013 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon AbbVie reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| March 03, 2014 Filed Mar 4, 2014 22:10 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 600 | $50.09 | $30,056.40 |
DisclosureSEC source: 0001179110-14-004322 · edgar.xml · nonDerivative · entry 5 ALBAN CARLOS · CIK 0001474632 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,138 Read SEC document |
| March 03, 2014 Filed Mar 4, 2014 22:10 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 400 | $50.09 | $20,036.40 |
DisclosureSEC source: 0001179110-14-004322 · edgar.xml · nonDerivative · entry 4 ALBAN CARLOS · CIK 0001474632 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,738 Read SEC document |
| March 03, 2014 Filed Mar 4, 2014 22:10 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 282 | $50.09 | $14,125.38 |
DisclosureSEC source: 0001179110-14-004322 · edgar.xml · nonDerivative · entry 3 ALBAN CARLOS · CIK 0001474632 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,138 Read SEC document |
| March 03, 2014 Filed Mar 4, 2014 22:10 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 1,600 | $50.09 | $80,137.60 |
DisclosureSEC source: 0001179110-14-004322 · edgar.xml · nonDerivative · entry 2 ALBAN CARLOS · CIK 0001474632 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,420 Read SEC document |
| February 28, 2014 Filed Mar 4, 2014 22:10 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 15,319 | $50.91 | $779,890.29 |
DisclosureSEC source: 0001179110-14-004322 · edgar.xml · nonDerivative · entry 1 ALBAN CARLOS · CIK 0001474632 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,020 Read SEC document |
| February 20, 2014 Filed Feb 24, 2014 22:06 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 81,500 | $0.00 Strike: $51.42 | $0.00 |
DisclosureSEC source: 0001179110-14-003466 · edgar.xml · derivative · entry 3 ALBAN CARLOS · CIK 0001474632 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,500 Underlying: Common stock · 81,500 shares Expires 2024-02-19 F3 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exerciseable in annual increments of 27,167 on 02/20/2015, 27,166 on 02/20/2016, and 27,167 on 02/20/2017. Read SEC document |
| February 20, 2014 Filed Feb 24, 2014 22:06 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 47,260 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-14-003466 · edgar.xml · nonDerivative · entry 1 ALBAN CARLOS · CIK 0001474632 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,339 F1 · shares: These securities represent performance vested restricted stock awards under the AbbVie 2013 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon AbbVie reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| May 01, 2013 Filed May 3, 2013 21:27 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (right to buy) · Derivative | 34,600 | $0.00 Strike: $28.31 | $0.00 |
DisclosureSEC source: 0001179110-13-007704 · edgar.xml · derivative · entry 15 ALBAN CARLOS · CIK 0001474632 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 34,600 shares Expires 2020-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| May 01, 2013 Filed May 3, 2013 21:27 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (right to buy) · Derivative | 21,000 | $0.00 Strike: $26.85 | $0.00 |
DisclosureSEC source: 0001179110-13-007704 · edgar.xml · derivative · entry 14 ALBAN CARLOS · CIK 0001474632 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 21,000 shares Expires 2019-10-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| May 01, 2013 Filed May 3, 2013 21:27 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (right to buy) · Derivative | 17,700 | $0.00 Strike: $28.13 | $0.00 |
DisclosureSEC source: 0001179110-13-007704 · edgar.xml · derivative · entry 13 ALBAN CARLOS · CIK 0001474632 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 17,700 shares Expires 2019-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| May 01, 2013 Filed May 3, 2013 21:27 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (right to buy) · Derivative | 33,900 | $0.00 Strike: $28.86 | $0.00 |
DisclosureSEC source: 0001179110-13-007704 · edgar.xml · derivative · entry 12 ALBAN CARLOS · CIK 0001474632 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 33,900 shares Expires 2018-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| May 01, 2013 Filed May 3, 2013 21:27 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (right to buy) · Derivative | 35,700 | $0.00 Strike: $27.29 | $0.00 |
DisclosureSEC source: 0001179110-13-007704 · edgar.xml · derivative · entry 11 ALBAN CARLOS · CIK 0001474632 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 35,700 shares Expires 2017-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| May 01, 2013 Filed May 3, 2013 21:27 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 27,664 | $45.68 | $1,263,683.22 |
DisclosureSEC source: 0001179110-13-007704 · edgar.xml · nonDerivative · entry 9 ALBAN CARLOS · CIK 0001474632 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,079 Read SEC document |
| May 01, 2013 Filed May 3, 2013 21:27 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 30,550 | $45.68 | $1,395,426.24 |
DisclosureSEC source: 0001179110-13-007704 · edgar.xml · nonDerivative · entry 8 ALBAN CARLOS · CIK 0001474632 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,743 Read SEC document |
| May 01, 2013 Filed May 3, 2013 21:27 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 27,320 | $45.66 | $1,247,562.34 |
DisclosureSEC source: 0001179110-13-007704 · edgar.xml · nonDerivative · entry 7 ALBAN CARLOS · CIK 0001474632 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,293 Read SEC document |
| May 01, 2013 Filed May 3, 2013 21:27 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 28,122 | $45.68 | $1,284,717.01 |
DisclosureSEC source: 0001179110-13-007704 · edgar.xml · nonDerivative · entry 6 ALBAN CARLOS · CIK 0001474632 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,613 Read SEC document |
| May 01, 2013 Filed May 3, 2013 21:27 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon stock, $0.01 par value | 34,600 | $28.31 | $979,602.12 |
DisclosureSEC source: 0001179110-13-007704 · edgar.xml · nonDerivative · entry 5 ALBAN CARLOS · CIK 0001474632 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,735 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2013 Filed May 3, 2013 21:27 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon stock, $0.01 par value | 21,000 | $26.85 | $563,791.20 |
DisclosureSEC source: 0001179110-13-007704 · edgar.xml · nonDerivative · entry 4 ALBAN CARLOS · CIK 0001474632 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,135 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2013 Filed May 3, 2013 21:27 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon stock, $0.01 par value | 17,700 | $28.13 | $497,814.27 |
DisclosureSEC source: 0001179110-13-007704 · edgar.xml · nonDerivative · entry 3 ALBAN CARLOS · CIK 0001474632 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,135 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2013 Filed May 3, 2013 21:27 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon stock, $0.01 par value | 33,900 | $28.86 | $978,448.92 |
DisclosureSEC source: 0001179110-13-007704 · edgar.xml · nonDerivative · entry 2 ALBAN CARLOS · CIK 0001474632 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,435 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2013 Filed May 3, 2013 21:27 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon stock, $0.01 par value | 35,700 | $27.29 | $974,395.80 |
DisclosureSEC source: 0001179110-13-007704 · edgar.xml · nonDerivative · entry 1 ALBAN CARLOS · CIK 0001474632 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,535 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2013 Filed Mar 4, 2013 22:09 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 12,960 | $36.73 | $476,020.80 |
DisclosureSEC source: 0001179110-13-004015 · edgar.xml · nonDerivative · entry 1 ALBAN CARLOS · CIK 0001474632 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,835 Read SEC document |
| February 19, 2013 Filed Feb 20, 2013 00:06 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 9,826 | $37.58 | $369,261.08 |
DisclosureSEC source: 0001179110-13-003031 · edgar.xml · nonDerivative · entry 2 ALBAN CARLOS · CIK 0001474632 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,795 Read SEC document |
| February 14, 2013 Filed Feb 20, 2013 00:06 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 115,830 | $0.00 Strike: $35.88 | $0.00 |
DisclosureSEC source: 0001179110-13-003031 · edgar.xml · derivative · entry 4 ALBAN CARLOS · CIK 0001474632 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,830 Underlying: Common stock · 115,830 shares Expires 2023-02-13 F3 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exerciseable in annual increments of 38,610 on 02/14/2014, 38,610 on 02/14/2015, and 38,610 on 02/14/2016. Read SEC document |
| February 14, 2013 Filed Feb 20, 2013 00:06 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 56,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-13-003031 · edgar.xml · nonDerivative · entry 1 ALBAN CARLOS · CIK 0001474632 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,621 F1 · shares: These securities represent performance vested restricted stock awards under the AbbVie 2013 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon AbbVie reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 05, 2013 Filed Feb 7, 2013 21:44 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (right to buy) · Derivative | 2,482 | $0.00 Strike: $33.80 | $0.00 |
DisclosureSEC source: 0001179110-13-002137 · edgar.xml · derivative · entry 4 ALBAN CARLOS · CIK 0001474632 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 2,482 shares Expires 2013-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2013 Filed Feb 7, 2013 21:44 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 2,325 | $37.28 | $86,676.00 |
DisclosureSEC source: 0001179110-13-002137 · edgar.xml · nonDerivative · entry 2 ALBAN CARLOS · CIK 0001474632 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,921 Read SEC document |
| February 05, 2013 Filed Feb 7, 2013 21:44 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon stock, $0.01 par value | 2,482 | $33.80 | $83,886.64 |
DisclosureSEC source: 0001179110-13-002137 · edgar.xml · nonDerivative · entry 1 ALBAN CARLOS · CIK 0001474632 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,246 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2012 Filed Dec 4, 2012 22:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 18,453 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-12-016883 · edgar.xml · nonDerivative · entry 2 ALBAN CARLOS · CIK 0001474632 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,696 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards will cliff vest after January 1, 2016, subject to AbbVie reaching a minimum average return on equity target for the period 2013 through 2015. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| November 16, 2012 Filed Dec 4, 2012 22:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 40,442 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-12-016883 · edgar.xml · nonDerivative · entry 3 ALBAN CARLOS · CIK 0001474632 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · Maria Cristina Alban 2007 Declaration of Trust Disclosed balance after: 40,442 F2 · balance_after: Held in the Maria Cristina Alban 2007 Declaration of Trust. The reporting person's spouse is trustee of the trust. The trust is revocable by his spouse. The reporting person disclaims beneficial ownership of these securities. Read SEC document |
| November 16, 2012 Filed Dec 4, 2012 22:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 40,442 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-12-016883 · edgar.xml · nonDerivative · entry 1 ALBAN CARLOS · CIK 0001474632 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,243 Read SEC document |
| October 15, 2012 Filed Oct 17, 2012 21:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 2,032 | $69.28 | $140,776.96 |
DisclosureSEC source: 0001179110-12-015251 · edgar.xml · nonDerivative · entry 2 ALBAN CARLOS · CIK 0001474632 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,685 Read SEC document |
| October 15, 2012 Filed Oct 17, 2012 21:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 4,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-12-015251 · edgar.xml · nonDerivative · entry 1 ALBAN CARLOS · CIK 0001474632 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,717 F1 · shares: Settlement of a performance-based restricted stock unit in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| September 25, 2012 Filed Sep 27, 2012 21:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 1,198 | $0.00 Strike: $57.25 | $0.00 |
DisclosureSEC source: 0001179110-12-014554 · edgar.xml · derivative · entry 3 ALBAN CARLOS · CIK 0001474632 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 1,198 shares Expires 2014-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| September 25, 2012 Filed Sep 27, 2012 21:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,198 | $70.00 | $83,860.00 |
DisclosureSEC source: 0001179110-12-014554 · edgar.xml · nonDerivative · entry 2 ALBAN CARLOS · CIK 0001474632 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,817 Read SEC document |
| September 25, 2012 Filed Sep 27, 2012 21:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 1,198 | $57.25 | $68,585.50 |
DisclosureSEC source: 0001179110-12-014554 · edgar.xml · nonDerivative · entry 1 ALBAN CARLOS · CIK 0001474632 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,015 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.